8 completed, 6 terminated, 1 active not recruiting, 1 recruiting. 18 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 8, Terminated 6, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT) Engasertib, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 3 | Recruiting | Vaderis Therapeutics AG | 240 | 2026-11-02 | 2026-11-13 |
| A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) N-Acetyl-L-Leucine, Placebo - Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T) | Phase 3 | Active not recruiting | IntraBio Inc | 60 | 2025-03-18 | 2026-11-04 |
| Open-Label Extension of EryDex Study IEDAT-04-2022 Dexamethasone sodium phosphate - Ataxia Telangiectasia | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 101 | 2024-12-11 | 2026-05-05 |
| Evaluate the Neurological Effects of EryDex on Subjects With A-T Dexamethasone sodium phosphate, Placebo - Ataxia Telangiectasia | Phase 3 | Completed | Quince Therapeutics S.p.A. | 105 | 2024-06-24 | 2026-04-30 |
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Completed | Cure HHT | 71 | 2023-05-08 | 2026-10-27 |
| Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Propranolol treatment, Placebo - Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease | Phase 3 | Terminated | University Hospital, Bordeaux | 15 | 2020-06-23 | 2026-06-23 |
| Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Anti-VEGF injections of bevacizumab, Laser - Retinal Telangiectasis, Coats Disease | Phase 3 | Terminated | Fondation Ophtalmologique Adolphe de Rothschild | 18 | 2019-10-24 | 2025-12-10 |
| Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study EryDex System - Ataxia Telangiectasia, Genetic Syndrome | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 104 | 2018-06-12 | 2024-10-08 |
| BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). Bevacizumab, sodium chloride 0.9% - Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic | Phase 3 | Completed | Hospices Civils de Lyon | 24 | 2017-09-28 | 2025-08-06 |
| Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT Mupirocin, Placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 3 | Unknown | Hospital Italiano de Buenos Aires | 40 | 2017-06-01 | 2016-11-15 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Bevacizumab, placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Terminated | Hospices Civils de Lyon | 80 | 2014-04-01 | 2015-11-20 |
| ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome tranexamic acid - Telangiectasia, Hereditary Hemorrhagic, Osler-Rendu Disease | Phase 3 | Completed | Hospices Civils de Lyon | 170 | 2006-09-01 | 2019-05-28 |
| Effect of Avastin in Juxtafoveal Telangiectasias Bevacizumab, Intravitreal injection of Bevacizumab - Telangiectasis | Phase 3 | Withdrawn | Asociación para Evitar la Ceguera en México | 2006-09-01 | 2024-05-30 | |
| Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Conjugated pneumococcal vaccine (Prevenar) - Ataxia Telangiectasia (AT) | Phase 3 | Completed | Institute of Child Health | 30 | 2006-06-01 | 2008-04-11 |
| Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) - Retina, Telangiectasis | Phase 3 | Completed | University of Sao Paulo | 31 | 2006-01-01 | 2008-07-23 |
| Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Tranexamic acid first, than placebo, First placebo, than Tranexamic acid. - Hereditary Hemorrhagic Telangiectasia | Phase 3 | Completed | University Hospital, Saarland | 23 | 2002-03-01 | 2009-12-15 |
| Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia soy protein isolate - Hereditary Hemorrhagic Telangiectasia | Phase 3 | Completed | National Center for Research Resources (NCRR) | 60 | 1996-01-01 | 2005-06-24 |
Telangiectasia, Hereditary Hemorrhagic (9) · Epistaxis (6) · Ataxia Telangiectasia (5) · Anemia (2) · Genetic Diseases, Inborn (2) · CREST Syndrome (1) · Disease (1) · Hematologic Diseases (1) · Peripheral Vascular Diseases (1) · Rare Diseases (1) · Raynaud Disease (1) · Retinal Neovascularization (1) · Retinal Telangiectasis (1) · Scleroderma, Diffuse (1)
Cardiovascular Diseases (18) · Vascular Diseases (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Cardiovascular Abnormalities (9) · Congenital Abnormalities (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Vascular Malformations (9) · Hematologic Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Hemorrhage (6) · Metabolic Diseases (6)
Bevacizumab (3) · dexamethasone 21-phosphate (2) · Cellulose (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · IB1001 (1) · Lasers (1) · Mupirocin (1) · Ointments (1) · Sodium Chloride (1) · Soybean Proteins (1) · Tranexamic Acid (1) · acetylleucine (1) · pazopanib (1)
Hospices Civils de Lyon (3) · Quince Therapeutics S.p.A. (3) · Asociación para Evitar la Ceguera en México (1) · Cure HHT (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Hospital Italiano de Buenos Aires (1) · Institute of Child Health (1) · IntraBio Inc (1) · Jose Soberon, MD (1) · National Center for Research Resources (NCRR) (1) · University Hospital, Bordeaux (1) · University Hospital, Saarland (1) · University of Sao Paulo (1) · Vaderis Therapeutics AG (1)
United States (7) · France (6) · Germany (6) · United Kingdom (6) · Spain (5) · Italy (4) · Norway (3) · Poland (3) · Switzerland (3) · Belgium (2) · Denmark (2) · Argentina (1) · Australia (1) · Brazil (1) · Hungary (1)
Dirk Thye, MD (2) · Guenter R Janhofer, MD, PhD (1) · James Gossage, MD (1) · Jose Soberon, MD (1) · Joshua R. Korzenik (1) · Marcelo MS Serra, MD (1) · Otacilio O Maia Jr, M.D. (1) · Urban W Geisthoff, Priv.-Doz. Dr.med. (1) · Veronica Kon-Jara, MD (1)
PMID 17659962, PMID 25005464, PMID 25040799, PMID 27599328, PMID 30191360, PMID 37592715, PMID 39917433, PMID 42309084, PMID 42600624
2016 (1), 2017 (1), 2018 (1), 2025 (1)